The response variability of the asthma patients to the standard pharmacotherapy

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


Background. The aim of this study was to analyse the group of patients with asthma, who prefer to use short-acting anticholinergics (SAMA) for relief of asthma attacks. At the same time, these patients are prescribed inhaled glucocorticosteroids (ICS) in combination with long-acting P2-agonists (LABA) as a basic therapy according to the standards. Tha aim. To study the cause of low efficacy of LABA in patients with asthma who do not have a sufficient response to SABA, as well as the probability of reducing of bronchial obstruction with LAMA. Materials and methods. 12 non-smoking adults with moderate to severe asthma (III-IV stage of GINA), receiving medium or high doses of ICS in combination with LABA as a basic therapy without adequate control over asthma symptoms were included in the study. First group of patients showed the efficacy of salbutamol (FEV1 reversibility was more than 12% and more than 200 ml after 400 ^g of salbutamol) and ipratropium bromide (SABA+SAMA+). Second group included patients with low response to salbutamol and positive test (FEVt reversibility) with ipratropium bromide (SABA-SAMA+). Spirometry was performed at baseline point and in 5, 10, 15, 30, 60, 120 and 240 min after inhalation of bronchodilator (salmeterol 50 ^g, formoterol 12 ^g and tiotropium bromide 18 ^g in the different days). Results. It was shown that SABA-SAMA+ phenotype asthma patients demonstrated low response to LABA: FEV1 increased up to 7.64±1.67%, 156.0±16.0 ml after salmeterol inhalation and up to 9.4±5.8%, 166.7±103.1 ml after formoterol inhalation (compared with a group of SABA+SAMA+, where the response to salmeterol was 20.81±2.42%, 551.43±93.94 ml and the response to formoterol was 30.21±6.75%, 718.57±140.78 ml, p<0.05), and a good response to LAMA (13.7±5.8% and 250.0±61.6). Conclusion. The results of the study allowed to define asthma phenotype with low bronchial obstruction reversibility to SABA and sufficient reversibility to SAMA (SABA-SAMA+). This group of asthma patients need the basic treatment with the combination of ICS and LABA and LAMA (tiotropium bromide).

Restricted Access

K S Pavlova

NRC Institute of Immunology FMBA of Russia

Email: ksenimedical@gmail.com

D S Mdinaradze

NRC Institute of Immunology FMBA of Russia

O M Kurbacheva

NRC Institute of Immunology FMBA of Russia

  1. Федеральные клинические рекомендации по диагностике и лечению бронхиальной астмы. Российское респираторное общество. 2018. Источник публикации: http://spulmo. ru
  2. Функциональная диагностика в пульмонологии, практическое руководство. Под ред. А.Г. Чучалина. 2009;64
  3. Global Initiative for Asthma (GINA) Global strategy for asthma management and prevention (2018 update). http:// ginasthma.org/.
  4. Курбачёва ОМ, Павлова КС. Возможно ли улучшение контроля бронхиальной астмы без увеличения доз глюкокортикостероидов? Практическая пульмонология. 2017;2:14-22
  5. Павлова КС, Мдинарадзе ДС, Кофиади ИА, Курбачёва ОМ. Роль генетических полиморфизмов Р2-адренорецептора в фармакологическом ответе на терапию бронхиальной астмы. Российский Аллергологический Журнал. 2019;(1):13-22

Views

Abstract - 36

PDF (Russian) - 0

PlumX

Dimensions

Refbacks

  • There are currently no refbacks.

Copyright (c) 2019 Russian Allergological Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies